Brought to you by 
Kite Pharma and bluebird work together on TCR therapies for HPV-associated cancers
24 Jun 2015
Executive Summary
Kite Pharma Inc. and bluebird bio Inc. will work together to develop next-generation T-cell receptor (TCR) candidates against human papillomavirus-associated cancers.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kite Pharma and bluebird work together on TCR therapies for HPV-associated cancers
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice